NEW YORK– December 19, 2013 — (BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) announced today that FETZIMA™ (levomilnacipran ER capsules), is now available in pharmacies throughout the United States. FETZIMA was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder (MDD), also known as depression, in adults in July 2013. […]
NEW YORK– December 9, 2013 — (BUSINESS WIRE) –Forest Laboratories, Inc. (NYSE:FRX) today announced appointments to its executive leadership team. The appointments are part of Forest’s announced plans to flatten and broaden the organization as part of Project Rejuvenate. “Today we are announcing an important step to rejuvenate our company by creating the first Forest Executive Team […]
Forest acquires exclusive rights to Saphris® in the United States for the treatment of schizophrenia and acute bipolar mania in adults for $240 million plus sales-based milestones and on-going supply payments Saphris is complementary to Forest’s existing CNS franchise and commercial infrastructure Agreement is expected to be immediately accretive to Forest NEW YORK — December […]
NEW YORK & BUDAPEST, Hungary– November 21, 2013 — (BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) and Gedeon Richter Plc. announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for cariprazine, an atypical antipsychotic for the treatment of schizophrenia and for the acute treatment of manic or […]
NEW YORK–November 11, 2013–(BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) today announced that Robert Bailey was appointed Senior Vice President, Chief Legal Officer General Counsel. In this role, Bailey will be responsible to manage the legal affairs of the Company, and will also serve as the company’s Corporate Secretary. Bailey will report to Brent Saunders, Chief Executive […]
NEW YORK–November 7, 2013–(BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories Holdings, Ltd. (collectively, “Forest”) announced today that they have entered into a settlement agreement with Actavis, Inc. and related companies and subsidiaries thereof, in patent infringement litigation brought by Forest in response to Actavis’s abbreviated new drug application (“ANDA”) seeking approval to market generic […]